Sergio Leonardi

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial
    Sergio Leonardi
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Heart 99:1282-7. 2013
  2. doi request reprint Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction
    Sergio Leonardi
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 60:2296-304. 2012
  3. doi request reprint Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous
    Sergio Leonardi
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 160:65-72. 2010
  4. doi request reprint Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial
    Sergio Leonardi
    Duke Clinical Research Institute, Durham, NC, USA
    Eur Heart J 34:1723-31. 2013
  5. doi request reprint Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial
    Sergio Leonardi
    Department of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Coron Artery Dis 24:321-7. 2013
  6. doi request reprint Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial
    Sergio Leonardi
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 163:768-776.e2. 2012
  7. doi request reprint Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends
    Pierluigi Tricoci
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 62:242-51. 2013
  8. doi request reprint Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome
    Sergio Leonardi
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Adv Cardiol 47:87-99. 2012
  9. doi request reprint Promises of PAR-1 inhibition in acute coronary syndrome
    Sergio Leonardi
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27705, USA
    Curr Cardiol Rep 14:32-9. 2012
  10. pmc Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review
    Sergio Leonardi
    Duke University Medical Center, The Duke Clinical Research Institute, P O Box 17969, Durham, NC 27715 7969, USA
    Eur Heart J 34:894-902d. 2013

Detail Information

Publications13

  1. doi request reprint A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial
    Sergio Leonardi
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Heart 99:1282-7. 2013
    ..To reassess the efficacy of cangrelor efficacy using the universal definition of myocardial infarction (MI)...
  2. doi request reprint Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction
    Sergio Leonardi
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 60:2296-304. 2012
    ..This study compared prognoses of myocardial infarction related to percutaneous coronary intervention (PCI, procedural MI) using increasing creatine kinase-myocardial band (CK-MB) thresholds with spontaneous MI...
  3. doi request reprint Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous
    Sergio Leonardi
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 160:65-72. 2010
    ..The INNOVATE-PCI study is a phase 2 randomized, double-blind, clopidogrel-controlled trial to evaluate the safety, tolerability, and preliminary efficacy of this novel antiplatelet agent in patients undergoing nonurgent PCI...
  4. doi request reprint Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial
    Sergio Leonardi
    Duke Clinical Research Institute, Durham, NC, USA
    Eur Heart J 34:1723-31. 2013
    ..In this analysis, we explored the effect of vorapaxar on myocardial infarction (MI)...
  5. doi request reprint Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial
    Sergio Leonardi
    Department of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Coron Artery Dis 24:321-7. 2013
    ..Using data from the CHAMPION percutaneous coronary intervention (PCI), we determined the relationship between clopidogrel started at least 5 days before PCI (maintenance of clopidogrel) and PCI-related enzymatic infarct size...
  6. doi request reprint Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial
    Sergio Leonardi
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 163:768-776.e2. 2012
    ..Cangrelor is an intravenous, potent, and reversible P2Y(12) inhibitor with fast onset and offset of action. We designed CHAMPION PHOENIX to evaluate the efficacy and safety of cangrelor in patients with atherosclerosis undergoing PCI...
  7. doi request reprint Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends
    Pierluigi Tricoci
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 62:242-51. 2013
    ....
  8. doi request reprint Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome
    Sergio Leonardi
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Adv Cardiol 47:87-99. 2012
    ..In this chapter we will discuss the rationale for developing this novel class of antiplatelet agents and specifically, the two compounds in most advanced clinical development, vorapaxar and atopaxar...
  9. doi request reprint Promises of PAR-1 inhibition in acute coronary syndrome
    Sergio Leonardi
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27705, USA
    Curr Cardiol Rep 14:32-9. 2012
    ..In this review we discuss the rationale for developing this novel class of agents with a focus on the two compounds in most advanced clinical development, vorapaxar (SCH 530348) and atopaxar (E5555)...
  10. pmc Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review
    Sergio Leonardi
    Duke University Medical Center, The Duke Clinical Research Institute, P O Box 17969, Durham, NC 27715 7969, USA
    Eur Heart J 34:894-902d. 2013
    ..Developing appropriate strategies for uniform implementation is required...
  11. doi request reprint Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
    Pierluigi Tricoci
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    N Engl J Med 366:20-33. 2012
    ..Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation...
  12. doi request reprint Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction
    Sergio Leonardi
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 164:502-8. 2012
    ..However, the frequency of CCC reporting has not been delineated, and the relationship of CCC reporting to hospital-level guidelines adherence for NSTEMI has not been investigated...
  13. doi request reprint Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555
    Sergio Leonardi
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Drugs 70:1771-83. 2010
    ..In this review we discuss this novel class of antiplatelet agents, focusing in particular on their therapeutic potential...